Antibody data
- Antibody Data
- Antigen structure
- References [54]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [5]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-13697 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-EGFR Antibody Cocktail
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA5-13697 targets Epidermal Growth Factor Receptor in IP applications and shows reactivity with Human samples. The MA5-13697 immunogen is partially purified EGFR from A431 cells (clone 528) and extracellular domain of recombinant human EGFR protein (clone 199.12).
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 528, 199.12
- Vial size
- 500 µL
- Concentration
- 0.2 mg/mL
- Storage
- 4° C
Submitted references Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling.
Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells.
PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.
mMAPS: a flow-proteometric technique to analyze protein-protein interactions in individual signaling complexes.
Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands.
Propranolol restricts the mobility of single EGF-receptors on the cell surface before their internalization.
Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays.
Monitoring the size and lateral dynamics of ErbB1 enriched membrane domains through live cell plasmon coupling microscopy.
A Miniaturized Ligand Binding Assay for EGFR.
Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.
Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.
Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex.
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Potential localization of putative stem/progenitor cells in human bulbar conjunctival epithelium.
High speed digital protein interaction analysis using microfluidic single molecule detection system.
IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.
Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity.
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.
EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.
Nuclear EGFR is required for cisplatin resistance and DNA repair.
EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2.
Intracellular MUC1 peptides inhibit cancer progression.
Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways.
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction.
Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation.
Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells.
Diacylglycerol kinase delta regulates protein kinase C and epidermal growth factor receptor signaling.
Intersectin regulates epidermal growth factor receptor endocytosis, ubiquitylation, and signaling.
The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3.
Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1.
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites.
Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex.
Geldanamycin-associated inhibition of intracellular trafficking is attributed to a co-purified activity.
Compromised reproductive function in adult female mice selectively expressing mutant ErbB-1 tyrosine kinase receptors in astroglia.
Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization.
1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor.
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Tyrosine-phosphorylated plakoglobin is associated with desmogleins but not desmoplakin after epidermal growth factor receptor activation.
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Intracellular retention and degradation of the epidermal growth factor receptor, two distinct processes mediated by benzoquinone ansamycins.
Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation.
A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation.
A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera.
A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera.
Hasegawa Y, Takahashi M, Ariki S, Asakawa D, Tajiri M, Wada Y, Yamaguchi Y, Nishitani C, Takamiya R, Saito A, Uehara Y, Hashimoto J, Kurimura Y, Takahashi H, Kuroki Y
Oncogene 2015 Feb 12;34(7):838-45
Oncogene 2015 Feb 12;34(7):838-45
Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells.
Huo L, Li CW, Huang TH, Lam YC, Xia W, Tu C, Chang WC, Hsu JL, Lee DF, Nie L, Yamaguchi H, Wang Y, Lang J, Li LY, Chen CH, Mishra L, Hung MC
American journal of translational research 2014;6(6):649-63
American journal of translational research 2014;6(6):649-63
PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.
Kuo HY, Huang YS, Tseng CH, Chen YC, Chang YW, Shih HM, Wu CW
Cell cycle (Georgetown, Tex.) 2014;13(19):3132-42
Cell cycle (Georgetown, Tex.) 2014;13(19):3132-42
mMAPS: a flow-proteometric technique to analyze protein-protein interactions in individual signaling complexes.
Chou CK, Lee HH, Tsou PH, Chen CT, Hsu JM, Yamaguchi H, Wang YN, Lee HJ, Hsu JL, Lee JF, Kameoka J, Hung MC
Science signaling 2014 Mar 4;7(315):rs1
Science signaling 2014 Mar 4;7(315):rs1
Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands.
Henriksen L, Grandal MV, Knudsen SL, van Deurs B, Grøvdal LM
PloS one 2013;8(3):e58148
PloS one 2013;8(3):e58148
Propranolol restricts the mobility of single EGF-receptors on the cell surface before their internalization.
Otero C, Linke M, Sanchez P, González A, Schaap IA
PloS one 2013;8(12):e83086
PloS one 2013;8(12):e83086
Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays.
Pötz O, Schneiderhan-Marra N, Henzler T, Herget T, Joos TO
Methods in molecular biology (Clifton, N.J.) 2012;795:191-202
Methods in molecular biology (Clifton, N.J.) 2012;795:191-202
Monitoring the size and lateral dynamics of ErbB1 enriched membrane domains through live cell plasmon coupling microscopy.
Rong G, Reinhard BM
PloS one 2012;7(3):e34175
PloS one 2012;7(3):e34175
A Miniaturized Ligand Binding Assay for EGFR.
Schwenk JM, Poetz O, Zeillinger R, Joos TO
International journal of proteomics 2012;2012:247059
International journal of proteomics 2012;2012:247059
Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.
Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, Nussler AK, Göttsch D, Münkel S, Bantel H, Kontermann RE, Pfizenmaier K
Cell death & disease 2012 Apr 12;3:e295
Cell death & disease 2012 Apr 12;3:e295
Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.
Yang X, Guo Z, Sun F, Li W, Alfano A, Shimelis H, Chen M, Brodie AM, Chen H, Xiao Z, Veenstra TD, Qiu Y
The Journal of biological chemistry 2011 Oct 14;286(41):36152-60
The Journal of biological chemistry 2011 Oct 14;286(41):36152-60
Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex.
Deb TB, Zuo AH, Wang Y, Barndt RJ, Cheema AK, Sengupta S, Coticchia CM, Johnson MD
American journal of physiology. Cell physiology 2011 May;300(5):C1139-54
American journal of physiology. Cell physiology 2011 May;300(5):C1139-54
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Potential localization of putative stem/progenitor cells in human bulbar conjunctival epithelium.
Qi H, Zheng X, Yuan X, Pflugfelder SC, Li DQ
Journal of cellular physiology 2010 Oct;225(1):180-5
Journal of cellular physiology 2010 Oct;225(1):180-5
High speed digital protein interaction analysis using microfluidic single molecule detection system.
Chou CK, Jing N, Yamaguchi H, Tsou PH, Lee HH, Chen CT, Wang YN, Hong S, Su C, Kameoka J, Hung MC
Lab on a chip 2010 Jul 21;10(14):1793-8
Lab on a chip 2010 Jul 21;10(14):1793-8
IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.
Poindexter NJ, Williams RR, Powis G, Jen E, Caudle AS, Chada S, Grimm EA
Experimental dermatology 2010 Aug;19(8):714-22
Experimental dermatology 2010 Aug;19(8):714-22
Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity.
Ahmed IS, Rohe HJ, Twist KE, Craven RJ
The Journal of biological chemistry 2010 Aug 6;285(32):24775-82
The Journal of biological chemistry 2010 Aug 6;285(32):24775-82
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.
Zhu H, Cao X, Ali-Osman F, Keir S, Lo HW
Cancer letters 2010 Aug 1;294(1):101-10
Cancer letters 2010 Aug 1;294(1):101-10
EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.
Zhang Y, Su H, Rahimi M, Tochihara R, Tang C
International journal of cancer 2009 Nov 1;125(9):2021-8
International journal of cancer 2009 Nov 1;125(9):2021-8
Nuclear EGFR is required for cisplatin resistance and DNA repair.
Hsu SC, Miller SA, Wang Y, Hung MC
American journal of translational research 2009 Mar 8;1(3):249-58
American journal of translational research 2009 Mar 8;1(3):249-58
EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2.
Klessner JL, Desai BV, Amargo EV, Getsios S, Green KJ
Molecular biology of the cell 2009 Jan;20(1):328-37
Molecular biology of the cell 2009 Jan;20(1):328-37
Intracellular MUC1 peptides inhibit cancer progression.
Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, Schroeder JA
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Jan 1;15(1):100-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Jan 1;15(1):100-9
Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways.
Joo CK, Kim HS, Park JY, Seomun Y, Son MJ, Kim JT
Oncogene 2008 Jan 24;27(5):614-28
Oncogene 2008 Jan 24;27(5):614-28
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, Truesdale AT, Shewchuk L, Wood ER
Cancer research 2008 Jan 15;68(2):571-9
Cancer research 2008 Jan 15;68(2):571-9
Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction.
Rajagopalan V, Zucker IH, Jones JA, Carlson M, Ma YJ
American journal of physiology. Heart and circulatory physiology 2008 Aug;295(2):H543-54
American journal of physiology. Heart and circulatory physiology 2008 Aug;295(2):H543-54
Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation.
Umebayashi K, Stenmark H, Yoshimori T
Molecular biology of the cell 2008 Aug;19(8):3454-62
Molecular biology of the cell 2008 Aug;19(8):3454-62
Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.
Xu W, Soga S, Beebe K, Lee MJ, Kim YS, Trepel J, Neckers L
British journal of cancer 2007 Sep 17;97(6):741-4
British journal of cancer 2007 Sep 17;97(6):741-4
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT
Cancer research 2007 Jun 15;67(12):5779-88
Cancer research 2007 Jun 15;67(12):5779-88
Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells.
Faivre EJ, Lange CA
Molecular and cellular biology 2007 Jan;27(2):466-80
Molecular and cellular biology 2007 Jan;27(2):466-80
Diacylglycerol kinase delta regulates protein kinase C and epidermal growth factor receptor signaling.
Crotty T, Cai J, Sakane F, Taketomi A, Prescott SM, Topham MK
Proceedings of the National Academy of Sciences of the United States of America 2006 Oct 17;103(42):15485-90
Proceedings of the National Academy of Sciences of the United States of America 2006 Oct 17;103(42):15485-90
Intersectin regulates epidermal growth factor receptor endocytosis, ubiquitylation, and signaling.
Martin NP, Mohney RP, Dunn S, Das M, Scappini E, O'Bryan JP
Molecular pharmacology 2006 Nov;70(5):1643-53
Molecular pharmacology 2006 Nov;70(5):1643-53
The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3.
Funes M, Miller JK, Lai C, Carraway KL 3rd, Sweeney C
The Journal of biological chemistry 2006 Jul 14;281(28):19310-9
The Journal of biological chemistry 2006 Jul 14;281(28):19310-9
Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1.
Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC
Journal of cellular biochemistry 2006 Aug 15;98(6):1570-83
Journal of cellular biochemistry 2006 Aug 15;98(6):1570-83
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL
Oncogene 2005 Sep 15;24(41):6213-21
Oncogene 2005 Sep 15;24(41):6213-21
Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.
Whitson KB, Whitson SR, Red-Brewer ML, McCoy AJ, Vitali AA, Walker F, Johns TG, Beth AH, Staros JV
Biochemistry 2005 Nov 15;44(45):14920-31
Biochemistry 2005 Nov 15;44(45):14920-31
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, Neckers L
Nature structural & molecular biology 2005 Feb;12(2):120-6
Nature structural & molecular biology 2005 Feb;12(2):120-6
Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.
Kansra S, Stoll SW, Johnson JL, Elder JT
Molecular biology of the cell 2004 Sep;15(9):4299-309
Molecular biology of the cell 2004 Sep;15(9):4299-309
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L
Cancer research 2004 Sep 15;64(18):6652-9
Cancer research 2004 Sep 15;64(18):6652-9
Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites.
Fan YX, Wong L, Deb TB, Johnson GR
The Journal of biological chemistry 2004 Sep 10;279(37):38143-50
The Journal of biological chemistry 2004 Sep 10;279(37):38143-50
Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex.
Schmidt MH, Hoeller D, Yu J, Furnari FB, Cavenee WK, Dikic I, Bögler O
Molecular and cellular biology 2004 Oct;24(20):8981-93
Molecular and cellular biology 2004 Oct;24(20):8981-93
Geldanamycin-associated inhibition of intracellular trafficking is attributed to a co-purified activity.
Barzilay E, Ben-Califa N, Supino-Rosin L, Kashman Y, Hirschberg K, Elazar Z, Neumann D
The Journal of biological chemistry 2004 Feb 20;279(8):6847-52
The Journal of biological chemistry 2004 Feb 20;279(8):6847-52
Compromised reproductive function in adult female mice selectively expressing mutant ErbB-1 tyrosine kinase receptors in astroglia.
Li B, Yang Z, Hou J, McCracken A, Jennings MA, Ma MY
Molecular endocrinology (Baltimore, Md.) 2003 Nov;17(11):2365-76
Molecular endocrinology (Baltimore, Md.) 2003 Nov;17(11):2365-76
Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization.
Schmidt MHH, Furnari FB, Cavenee WK, Bögler O
Proceedings of the National Academy of Sciences of the United States of America 2003 May 27;100(11):6505-10
Proceedings of the National Academy of Sciences of the United States of America 2003 May 27;100(11):6505-10
1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor.
Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD, Barbieri MA, Dusso A
The Journal of biological chemistry 2002 Oct 11;277(41):38965-71
The Journal of biological chemistry 2002 Oct 11;277(41):38965-71
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG
Journal of the National Cancer Institute 2001 Sep 19;93(18):1375-84
Journal of the National Cancer Institute 2001 Sep 19;93(18):1375-84
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG
Journal of the National Cancer Institute 2001 Sep 19;93(18):1375-84
Journal of the National Cancer Institute 2001 Sep 19;93(18):1375-84
Tyrosine-phosphorylated plakoglobin is associated with desmogleins but not desmoplakin after epidermal growth factor receptor activation.
Gaudry CA, Palka HL, Dusek RL, Huen AC, Khandekar MJ, Hudson LG, Green KJ
The Journal of biological chemistry 2001 Jul 6;276(27):24871-80
The Journal of biological chemistry 2001 Jul 6;276(27):24871-80
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM
Molecular cancer therapeutics 2001 Dec;1(2):85-94
Molecular cancer therapeutics 2001 Dec;1(2):85-94
Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME
Cancer research 2000 Jun 1;60(11):3081-7
Cancer research 2000 Jun 1;60(11):3081-7
Intracellular retention and degradation of the epidermal growth factor receptor, two distinct processes mediated by benzoquinone ansamycins.
Supino-Rosin L, Yoshimura A, Yarden Y, Elazar Z, Neumann D
The Journal of biological chemistry 2000 Jul 21;275(29):21850-5
The Journal of biological chemistry 2000 Jul 21;275(29):21850-5
Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation.
Tikhomirov O, Carpenter G
The Journal of biological chemistry 2000 Aug 25;275(34):26625-31
The Journal of biological chemistry 2000 Aug 25;275(34):26625-31
A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation.
Supino-Rosin L, Yoshimura A, Altaratz H, Neumann D
European journal of biochemistry 1999 Jul;263(2):410-9
European journal of biochemistry 1999 Jul;263(2):410-9
A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera.
Baron AT, Lafky JM, Connolly DC, Peoples J, O'Kane DJ, Suman VJ, Boardman CH, Podratz KC, Maihle NJ
Journal of immunological methods 1998 Oct 1;219(1-2):23-43
Journal of immunological methods 1998 Oct 1;219(1-2):23-43
A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera.
Baron AT, Lafky JM, Connolly DC, Peoples J, O'Kane DJ, Suman VJ, Boardman CH, Podratz KC, Maihle NJ
Journal of immunological methods 1998 Oct 1;219(1-2):23-43
Journal of immunological methods 1998 Oct 1;219(1-2):23-43
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of EGFR was done on A-431 cells. Cells were fixed with 70% ethanol for 10 minutes, permeabilized with 0.25% Triton™ X-100 for 20 minutes, and blocked with 5% BSA for 30 minutes at room temperature. Cells were labeled with EGFR Mouse Monoclonal Antibody (MA513697, red histogram) or with mouse isotype control (yellow histogram) at 3-5 ug/million cells in 2.5% BSA. After incubation at room temperature for 2 hours, the cells were labeled with Alexa Fluor® 488 Rabbit Anti-Mouse Secondary Antibody (A11059) at a dilution of 1:400 for 30 minutes at room temperature. The representative 10,000 cells were acquired and analyzed for each sample using an Attune® Acoustic Focusing Cytometer. The purple histogram represents unstained control cells and the green histogram represents no-primary-antibody control.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of Epidermal Growth Factor Receptor using Epidermal Growth Factor Receptor Monoclonal Antibody (Product # MA5-13697) on Native Human A431 Cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of Epidermal Growth Factor Receptor using Epidermal Growth Factor Receptor Monoclonal Antibody (Product # MA5-13697) on denatured Human A431 Cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of EGFR was done on 90% confluent log phase A431 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled EGFR (528 + 199.12) Mouse Monoclonal Antibody (Product # MA5-13697) at 2 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing membranous localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- IP-MS enrichment of EGFR (LFQ intensity): EGFR was enriched 119-fold from A549 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Product # 90409) and EGFR antibody (Product # MA5-13697). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of EGFR was performed using 90% confluent log phase A-431 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with EGFR Mouse monoclonal antibody (Product # MA5-13697) at 5 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing membranous localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.